Heterocyclic modulators of nuclear receptors

Details Heterocyclic modulators of nuclear receptors Heterocyclic modulators of nuclear receptors

2002-12-20

2004-02-24

Lambkin, Deborah C. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S369000, C514S370000, C548S180000, C548S190000

Reexamination Certificate

active

06696473

ABSTRACT:

FIELD
Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of orphan nuclear receptors.
BACKGROUND
Nuclear Receptors
Nuclear receptors are a superfamily of regulatory proteins that are structurally and functionally related and are receptors for, e.g., steroids, retinoids, vitamin D and thyroid hormones (see, e.g., Evans (1988)
Science
240:889-895). These proteins bind to cis-acting elements in the promoters of their target genes and modulate gene expression in response to ligands for the receptors.
Nuclear receptors can be classified based on their DNA binding properties (see, e.g., Evans, supra and Glass (1994)
Endocr. Rev
. 15:391-407). For example, one class of nuclear receptors includes the glucocorticoid, estrogen, androgen, progestin and mineralocorticoid receptors which bind as homodimers to hormone response elements (HREs) organized as inverted repeats (see, e.g., Glass, supra). A second class of receptors, including those activated by retinoic acid, thyroid hormone, vitamin D
3
, fatty acids/peroxisome proliferators (i.e., peroxisome proliferator activated receptor (PPAR)) and ecdysone, bind to HREs as heterodimers with a common partner, the retinoid X receptors (i.e., RXRs, also known as the 9-cis retinoic acid receptors; see, e.g., Levin et al. (1992)
Nature
355:359-361 and Heyman et al. (1992)
Cell
68:397-406).
RXRs are unique among the nuclear receptors in that they bind DNA as a homodimer and are required as a heterodimeric partner for a number of additional nuclear receptors to bind DNA (see, e.g., Mangelsdorf et al. (1995)
Cell
83:841-850). The latter receptors, termed the class II nuclear receptor subfamily, include many which are established or implicated as important regulators of gene expression. There are three RXR genes (see, e.g., Mangelsdorf et al. (1992)
Genes Dev
. 6:329-344), coding for RXR&agr;, -&bgr;, and -&ggr;, all of which are able to heterodimerize with any of the class II receptors, although there appear to be preferences for distinct RXR subtypes by partner receptors in vivo (see, e.g., Chiba et al. (1997)
Mol. Cell. Biol
. 17:3013-3020). In the adult liver, RXR&agr; is the most abundant of the three RXRs (see, e.g., Mangelsdorf et al. (1992)
Genes Dev
. 6:329-344), suggesting that it might have a prominent role in hepatic functions that involve regulation by class II nuclear receptors. See also, Wan et al. (2000)
Mol. Cell. Biol
. 20:4436-4444.
Orphan Nuclear Receptors
Included in the nuclear receptor superfamily of regulatory proteins are nuclear receptors for whom the ligand is known and those which lack known ligands. Nuclear receptors falling in the latter category are referred to as orphan nuclear receptors. The search for activators for orphan receptors has led to the discovery of previously unknown signaling pathways (see, e.g., Levin et al., (1992), supra and Heyman et al., (1992), supra). For example, it has been reported that bile acids, which are involved in physiological processes such as cholesterol catabolism, are ligands for FXR (infra).
Since it is known that products of intermediary metabolism act as transcriptional regulators in bacteria and yeast, such molecules may serve similar functions in higher organisms (see, e.g., Tomkins (1975)
Science
189:760-763 and O'Malley (1989)
Endocrinology
125:1119-1120). For example, one biosynthetic pathway in higher eukaryotes is the mevalonate pathway, which leads to the synthesis of cholesterol, bile acids, porphyrin, dolichol, ubiquinone, carotenoids, retinoids, vitamin D, steroid hormones and farnesylated proteins.
FXR
FXR (originally isolated as RIP14 (retinoid X receptor-interacting protein-14), see, e.g., Seol et al. (1995)
Mol. Endocrinol
. 9:72-85) is a member of the nuclear hormone receptor superfamily and is primarily expressed in the liver, kidney and intestine (see, e.g., Seol et al., supra and Forman et al. (1995)
Cell
81:687-693). It functions as a heterodimer with the retinoid X receptor (RXR) and binds to response elements in the promoters of target genes to regulate gene transcription. The FXR-RXR heterodimer binds with highest affinity to an inverted repeat-1 (IR-1) response element, in which consensus receptor-binding hexamers are separated by one nucleotide. FXR is part of an interrelated process, in that FXR is activated by bile acids (the end product of cholesterol metabolism) (see, e.g., Makishima et al. (1999)
Science
284:1362-1365, Parks et al. (1999)
Science
284:1365-1368, Wang et al. (1999)
Mol. Cell
. 3:543-553), which serve to inhibit cholesterol catabolism. See also, Urizar et al. (2000)
J. Biol. Chem
. 275:39313-39317.
LXR&agr; and LXR&bgr;
LXR&agr; is found predominantly in the liver, with lower levels found in kidney, intestine, spleen and adrenal tissue (see, e.g., Willy, et al. (1995)
Gene Dev
. 9(9):1033-1045). LXR&bgr;, also known as UR (ubiquitous receptor), is ubiquitous in mammals and was found in nearly all tissues examined. LXRs are activated by certain naturally occurring, oxidized derivatives of cholesterol (see, e.g., Lehmann, et al. (1997)
J. Biol. Chem
. 272(6):3137-3140). LXR&agr; is activated by oxycholesterol and promotes cholesterol metabolism (Peet et al. (1998)
Cell
93:693-704). Thus, LXRs appear to play a role in, e.g., cholesterol metabolism (see, e.g., Janowski, et al. (1996)
Nature
383:728-731).
Nuclear Receptors and Disease
Nuclear receptor activity has been implicated in a variety of diseases and disorders, including, but not limited to, hypercholesterolemia (see, e.g., International Patent Application Publication No. WO 00/57915), osteoporosis and vitamin deficiency (see, e.g., U.S. Pat. No. 6,316,5103), hyperlipoproteinemia (see, e.g., International Patent Application Publication No. WO 01/60818), hypertriglyceridemia, lipodystrophy, peripheral occlusive disease, ischemic stroke, hyperglycemia and diabetes mellitus (see, e.g., International Patent Application Publication No. WO 01/82917), atherosclerosis and gallstones (see, e.g., International Patent Application Publication No. WO 00/37077), disorders of the skin and mucous membranes (see, e.g., U.S. Pat. Nos. 6,184,215 and 6,187,814, and International Patent Application Publication No. WO 98/32444), acne (see, e.g., International Patent Application Publication No. WO 00/49992), and cancer, Parkinson's disease and Alzheimer's disease (see, e.g., International Patent Application Publication No. WO 00/17334). Activity of nuclear receptors, including FXR, LXRs and/or orphan nuclear receptors, has been implicated in physiological processes including, but not limited to, bile acid biosynthesis, cholesterol metabolism or catabolism, and modulation of cholesterol 7&agr;-hydroxylase gene (CYP7A1) transcription (see, e.g., Chiang et al. (2000)
J. Biol. Chem
. 275:10918-10924), HDL metabolism (see, e.g., Urizar et al. (2000)
J. Biol. Chem
. 275:39313-39317), hyperlipidemia, cholestasis, and increased cholesterol efflux and increased expression of ATP binding cassette transporter protein (ABC1) (see, e.g., International Patent Application Publication No. WO 00/78972).
Thus, there is a need for compounds, compositions and methods of modulating the activity of nuclear receptors, including FXR, LXRs and/or orphan nuclear receptors. Such compounds are useful in the treatment, prevention, or amelioration of one or more symptoms of diseases or disorders in which nuclear receptor activity is implicated.
SUMMARY
Compounds for use in compositions and methods for modulating the activity of nuclear receptors are provided. In particular, compounds for use in compositions and methods for modulating farnesoid X receptor (FXR), liver X receptors (LXR&agr; and LXR&bgr;) and/or orphan nuclear receptors, are provided. In certain embodiments, the compounds are heterocyclic compounds that are substituted with a heterocyclylene group and an imine moiety. In one embodiment, the compounds provided herein are agonists of FXR and/or LXR.

Affiliated with

Also associated with

Rating

Heterocyclic modulators of nuclear receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic modulators of nuclear receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic modulators of nuclear receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3279010